Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBIT: 2019-2025

Historic EBIT for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$9.8 million.

  • Benitec Biopharma's EBIT fell 77.25% to -$9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$41.8 million, marking a year-over-year decrease of 85.70%. This contributed to the annual value of -$41.8 million for FY2025, which is 85.70% down from last year.
  • Latest data reveals that Benitec Biopharma reported EBIT of -$9.8 million as of Q2 2025, which was up 35.87% from -$15.3 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's EBIT ranged from a high of -$3.5 million in Q1 2022 and a low of -$15.3 million during Q1 2025.
  • For the 3-year period, Benitec Biopharma's EBIT averaged around -$7.3 million, with its median value being -$5.8 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first climbed by 8.78% in 2022, then slumped by 270.32% in 2025.
  • Benitec Biopharma's EBIT (Quarterly) stood at -$4.8 million in 2021, then declined by 16.03% to -$5.6 million in 2022, then decreased by 23.48% to -$6.9 million in 2023, then crashed by 55.98% to -$10.8 million in 2024, then crashed by 77.25% to -$9.8 million in 2025.
  • Its EBIT stands at -$9.8 million for Q2 2025, versus -$15.3 million for Q1 2025 and -$10.8 million for Q4 2024.